Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Nanoparticle-based delivery platforms for mRNA vaccine development

  • Received: 21 June 2020 Accepted: 16 August 2020 Published: 20 August 2020
  • Conventional vaccines have saved millions of lives, and new vaccines have also been developed; however, an urgent need for an efficient vaccine against SARS-CoV-2 showed us that vaccine development technologies should be improved more to obtain prophylactic agents rapidly during pandemic diseases. One of the next-generation vaccine technologies is utilization of mRNA molecules encoding antigens. The mRNA vaccines offer many advantages compared to conventional and other subunit vaccines. For instance, mRNA vaccines are relatively safe since they do not cause disease and mRNA does not integrate into the genome. mRNA vaccines also provide diverse types of immune responses resulting in the activation of CD4+ and CD8+ T cells. However, utilization of mRNA molecules also has some drawbacks such as degradation by ubiquitous nucleases in vivo. Nanoparticles (NPs) are delivery platforms that carry the desired molecule, a drug or a vaccine agent, to the target cell such as antigen presenting cells in the case of vaccine development. NP platforms also protect mRNA molecules from the degradation by nucleases. Therefore, efficient mRNA vaccines can be obtained via utilization of NPs in the formulation. Although lipid-based NPs are widely preferred in vaccine development due to the nature of cell membrane, there are various types of other NPs used in vaccine formulations, such as virus-like particles (VLPs), polymers, polypeptides, dendrimers or gold NPs. Improvements in the NP delivery technologies will contribute to the development of mRNA vaccines with higher efficiency.

    Citation: Sezer Okay, Öznur Özge Özcan, Mesut Karahan. Nanoparticle-based delivery platforms for mRNA vaccine development[J]. AIMS Biophysics, 2020, 7(4): 323-338. doi: 10.3934/biophy.2020023

    Related Papers:

    [1] Jing Hu, Zhijun Liu, Lianwen Wang, Ronghua Tan . Extinction and stationary distribution of a competition system with distributed delays and higher order coupled noises. Mathematical Biosciences and Engineering, 2020, 17(4): 3240-3251. doi: 10.3934/mbe.2020184
    [2] Meng Gao, Xiaohui Ai . A stochastic Gilpin-Ayala mutualism model driven by mean-reverting OU process with Lévy jumps. Mathematical Biosciences and Engineering, 2024, 21(3): 4117-4141. doi: 10.3934/mbe.2024182
    [3] Helong Liu, Xinyu Song . Stationary distribution and extinction of a stochastic HIV/AIDS model with nonlinear incidence rate. Mathematical Biosciences and Engineering, 2024, 21(1): 1650-1671. doi: 10.3934/mbe.2024072
    [4] Cristina Anton, Alan Yong . Stochastic dynamics and survival analysis of a cell population model with random perturbations. Mathematical Biosciences and Engineering, 2018, 15(5): 1077-1098. doi: 10.3934/mbe.2018048
    [5] Ying He, Junlong Tao, Bo Bi . Stationary distribution for a three-dimensional stochastic viral infection model with general distributed delay. Mathematical Biosciences and Engineering, 2023, 20(10): 18018-18029. doi: 10.3934/mbe.2023800
    [6] H. J. Alsakaji, F. A. Rihan, K. Udhayakumar, F. El Ktaibi . Stochastic tumor-immune interaction model with external treatments and time delays: An optimal control problem. Mathematical Biosciences and Engineering, 2023, 20(11): 19270-19299. doi: 10.3934/mbe.2023852
    [7] Sanling Yuan, Xuehui Ji, Huaiping Zhu . Asymptotic behavior of a delayed stochastic logistic model with impulsive perturbations. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1477-1498. doi: 10.3934/mbe.2017077
    [8] Yan Xie, Zhijun Liu, Ke Qi, Dongchen Shangguan, Qinglong Wang . A stochastic mussel-algae model under regime switching. Mathematical Biosciences and Engineering, 2022, 19(5): 4794-4811. doi: 10.3934/mbe.2022224
    [9] Fathalla A. Rihan, Hebatallah J. Alsakaji . Analysis of a stochastic HBV infection model with delayed immune response. Mathematical Biosciences and Engineering, 2021, 18(5): 5194-5220. doi: 10.3934/mbe.2021264
    [10] Ming-Zhen Xin, Bin-Guo Wang, Yashi Wang . Stationary distribution and extinction of a stochastic influenza virus model with disease resistance. Mathematical Biosciences and Engineering, 2022, 19(9): 9125-9146. doi: 10.3934/mbe.2022424
  • Conventional vaccines have saved millions of lives, and new vaccines have also been developed; however, an urgent need for an efficient vaccine against SARS-CoV-2 showed us that vaccine development technologies should be improved more to obtain prophylactic agents rapidly during pandemic diseases. One of the next-generation vaccine technologies is utilization of mRNA molecules encoding antigens. The mRNA vaccines offer many advantages compared to conventional and other subunit vaccines. For instance, mRNA vaccines are relatively safe since they do not cause disease and mRNA does not integrate into the genome. mRNA vaccines also provide diverse types of immune responses resulting in the activation of CD4+ and CD8+ T cells. However, utilization of mRNA molecules also has some drawbacks such as degradation by ubiquitous nucleases in vivo. Nanoparticles (NPs) are delivery platforms that carry the desired molecule, a drug or a vaccine agent, to the target cell such as antigen presenting cells in the case of vaccine development. NP platforms also protect mRNA molecules from the degradation by nucleases. Therefore, efficient mRNA vaccines can be obtained via utilization of NPs in the formulation. Although lipid-based NPs are widely preferred in vaccine development due to the nature of cell membrane, there are various types of other NPs used in vaccine formulations, such as virus-like particles (VLPs), polymers, polypeptides, dendrimers or gold NPs. Improvements in the NP delivery technologies will contribute to the development of mRNA vaccines with higher efficiency.


    According to the definition of [1], mutualism is the interaction of two/many species that benefits both/each other. As a common occurrence in nature, the mutualism interaction has an important impact and is well documented in many types of communities. Mutualism can be obligate or facultative, more specifically, an obligate mutualist is a species which requires the presence of another species for its survival [2] while a facultative mutualist is one which benefits in the same way from the association with another species but will be survive in its absence [3]. In recent years many mutualism models have been studied intensively and some good results have been obtained, for details to see stability and bifurcation [4,5,6,7,8,9,10,11,12], persistence and extinction [5,7,8,11,13,14,15,16,17,18,19,20], periodic solution and almost periodic solution [20,21,22,23,24], optimal control [25,26], and stationary distribution [27,28].

    Recalling many of the above studies, we can see that the distributed delay does't been taken into account. In fact the evolution of a species may reply on an average over past population or the cumulative effect of the past history, and distributed delays are often incorporated into populations models, for details to see references [30,31,32,33,34,35,36,37,38,39,40]. Particularly, the following Gamma distribution initially given by MacDonald [32]

    K(t)=tnσn+1eσtn!,  σ>0,n=0,1,2,,

    is usually used for the delay kernels. It is well known that there exist two types of kernels: weak kernel and strong kernel, which respectively, represented by

    K(t)=σeσt (n=0,weak kernel),  K(t)=tσ2eσt (n=1,strong kernel).  (1.1)

    Both weak kernel and strong kernel own different biological meanings: the former implies that the maximum weighted response of the growth rate is due to current population density while past densities have exponentially decreasing influence, and the latter indicate that the maximum influence on the growth rate response at some time is due to population density at the previous time (see [41]).

    On the other hand, the deterministic models may be necessary to incorporate the environmental noises into these models. Nisbet and Gurney [42] and May[43] suggested that the growth rates in population systems should own stochasticity and emerge random fluctuation to a certain degree. Thus, some noise sources were incorporated and then corresponding stochastic models were established. However, in many excellent investigations the authors assumed that one noise source only had an effect on the intrinsic growth rate of one species. Obviously, a reasonable idea is to consider that one noise source has influence not only on the intrinsic growth rate of one species but also on that of other species.

    Inspired by the above arguments, in the next section we introduce a stochastic facultative mutualism model with distributed delays and strong kernels (see model (2.3)). Survival analysis and stationary distribution will become two topics of our whole research because the survival analysis reveals the persistence or extinction of one or more species in random environment and the stationary distribution is concerned with the stochastic statistical characteristic of the long-term behaviours of the sample trajectories. To the best of our knowledge, there are few published papers concerning model (2.3). The rest of this work is organized as follows. In Section 3, we present the main results including extinction exponentially, persistence in the mean, permanent in time average. In Section 4, we devote to investigating the existence and uniqueness of stationary distribution. In Section 5, numerical simulations are given to support our findings. A brief discussion on the biological meanings is shown in Section 6.

    For the final export of the model we will discuss, let us first introduce the following facultative mutualism model with saturation effect which corresponds to a deterministic competitive model proposed by Gopalsamy [29]

    {dx1(t)=x1(t)[a1b1x1(t)+c1x2(t)1+x2(t)]dt,dx2(t)=x2(t)[a2b2x2(t)+c2x1(t)1+x1(t)]dt, (2.1)

    where xi (i=1,2) are the densities of two species, ai>0 denote the intrinsic growth rates, bi>0 are the intraspecific competition rates, ci>0 are the interspecific mutualism rates and the nonlinear term c1x2/(1+x2) (or c2x1/(1+x1)) reflects a saturation effect for large enough x2 (or x1).

    With the idea of distributed delays and strong kernels, model (2.1) becomes a delayed version

    {dx1(t)=x1(t)[a1b1x1(t)+c1t(ts)σ22eσ2(ts)x2(s)1+x2(s)ds]dt,dx2(t)=x2(t)[a2b2x2(t)+c2t(ts)σ21eσ1(ts)x1(s)1+x1(s)ds]dt. (2.2)

    Similar to [44], we use two coupling noise sources to model the random perturbations and derive a new stochastic model

    {dx1(t)=x1(t)[a1b1x1(t)+c1t(ts)σ22eσ2(ts)x2(s)1+x2(s)ds]dt+2i=1α1ix1(t)dBi(t),dx2(t)=x2(t)[a2b2x2(t)+c2t(ts)σ21eσ1(ts)x1(s)1+x1(s)ds]dt+2i=1α2ix2(t)dBi(t), (2.3)

    with initial values xi(s)=ϕi(s)0, s(,0] and ϕi(0)>0, where ϕi are continuous bounded functions on (,0]. Bi(t) are standard independent Brownian motions defined on a complete probability space (Ω,F,{Ft}t0,P) with a filtration {Ft}t0 satisfying the usual conditions. And α21i, α22i denote the coupling noise intensities.

    Assign

    m1(t)=t(ts)σ21eσ1(ts)x1(s)1+x1(s)ds, m2(t)=t(ts)σ22eσ2(ts)x2(s)1+x2(s)ds,n1(t)=tσ1eσ1(ts)x1(s)1+x1(s)ds, n2(t)=tσ2eσ2(ts)x2(s)1+x2(s)ds. (2.4)

    With the help of chain techniques, the delayed stochastic facultative mutualism model (2.3) is transformed into an equivalent undelayed stochastic six-dimensional system

    {dx1(t)=x1(t)[a1b1x1(t)+c1m2(t)]dt+α11x1(t)dB1(t)+α12x1(t)dB2(t),dx2(t)=x2(t)[a2b2x2(t)+c2m1(t)]dt+α21x2(t)dB1(t)+α22x2(t)dB2(t),dm1(t)=σ1(n1(t)m1(t))dt,dm2(t)=σ2(n2(t)m2(t))dt,dn1(t)=σ1(x1(t)1+x1(t)n1(t))dt,dn2(t)=σ2(x2(t)1+x2(t)n2(t))dt. (2.5)

    with initial value (x1(0),x2(0),m1(0),m2(0),n1(0),n2(0)), where

    xi(0)=ϕi(0), mi(0)=0sσ2ieσisϕi(s)1+ϕi(s)ds, ni(0)=0σieσisϕi(s)1+ϕi(s)ds, i=1,2.

    To show the novelty of our work, we explicate the following two facts:

    (I) Zuo et al. [36] recently investigated the following stochastic two-species cooperative model with distributed delays and weak kernels

    {dx1(t)=x1(t)[a1b1x1(t)+c1tσ2eσ2(ts)x2(s)ds]dt+α11x1(t)dB1(t),dx2(t)=x2(t)[a2b2x2(t)+c2tσ1eσ1(ts)x1(s)ds]dt+α22x2(t)dB2(t). (2.6)

    Obviously, there exists a limitation in model (2.6): with the increase of one cooperator's density, its cooperative capacity will increase and tend to infinity (see citσjeσj(ts)xj(s)ds). But in real life, this interaction between different species should be upper-bounded (a similar argument can be seen in [45]). In our model (2.3), the interspecific mutualism terms cit(ts)σ2ieσi(ts)xj(s)1+xj(s)ds show saturation effects. Also, by the chain techniques, model (2.6) can be transformed into an equivalent four-dimensional system (see model (2.2) in [36]) whose dimension is lower than the above six-dimensional system (2.5). Finally, we must point out that there are two noise sources in model (2.6), but one noise source only has an effect on one species. It is easy to see that one noise source affects two species at the same time in model (2.3).

    (II) In a recent investigation, Ning et al. [40] discussed a stochastic competitive model with distributed delays and weak kernels

    {dx1(t)=x1(t)[a1b1x1(t)c1tσ2eσ2(ts)x2(s)1+x2(s)ds]dt+2i=1α1ix1(t)dBi(t),dx2(t)=x2(t)[a2b2x2(t)c2tσ1eσ1(ts)x1(s)1+x1(s)ds]dt+2i=1α2ix2(t)dBi(t). (2.7)

    Clearly, there exists a remarkably different mechanism of action between model (2.3) and model (2.7) because the former is interspecific mutualism (see the positive feedback parameters ci) and the latter is interspecific competition (see the negative feedback parameters ci). The strong kernel functions of our model (2.3) differs distinctly from the weak kernel functions of the above model (2.7) (also see Eq (1.1)). By the chain techniques, an equivalent undelayed six-dimensional system to model (2.3) is also different from that of the undelayed four-dimensional system to model (2.7) (see model (3) in [40]).

    As a continuation of previous work [40], our main purpose of this contribution is to investigate the effects of both coupling noise sources on the long-time behaviors of facultative mutualism model (2.3) with distributed delays and strong kernels by analyzing its equivalent system (2.5). For the convenience of the subsequent analysis, we list the following two definitions.

    Definition 2.1. Signals and abbreviations are defined in Table 1.

    Table 1.  Signal abbreviation.
    Signal x(t) x x
    Expression t1t0x(s)ds lim inft+x(t) lim supt+x(t)

     | Show Table
    DownLoad: CSV

    Definition 2.2. Survival results of species are defined in Table 2.

    Table 2.  Survival of species.
    Cases Conditions
    x-Extinct exponentially (EE) lim supt+t1lnx(t)<ϖ1 a.s. (ϖ1>0)
    x-Persistence in the mean (PM) limt+x(t)=ϖ2 a.s. (ϖ2>0)
    x-Permanent in time average (PTA) ϖ3x(t)x(t)ϖ4 a.s. (ϖ3, ϖ4>0)

     | Show Table
    DownLoad: CSV

    This section is determined to analyze the survival of system (2.5). For the convenience of the subsequent discussion, we first estimate mi(t) and ni(t).

    Lemma 3.1. mi(t), ni(t)1 and limt+mi(t)/t=limt+ni(t)/t=0, i=1,2.

    Proof. We first consider the upper bound of mi(t). It follows from Eq (2.4) that

    mi(t)=t(ts)σ2ieσi(ts)xi(s)1+xi(s)dst(ts)σ2ieσi(ts)ds=1, i=1,2. (3.1)

    Also, we obtain from Eq (2.4) that

    ni(t)=tσieσi(ts)xi(s)1+xi(s)dstσieσi(ts)ds=1, i=1,2. (3.2)

    Obviously, Eqs (3.1) and (3.2) imply that limt+mi(t)/t=0, limt+ni(t)/t=0, i=1,2.

    We continue to give the following fundamental lemma on the global existence and uniqueness of positive solution to system (2.5).

    Lemma 3.2. For any initial value X(0)=(x1(0),x2(0),m1(0),m2(0),n1(0),n2(0))>0, system (2.5) admits a unique global solution X(t)=(x1(t),x2(t),m1(t),m2(t),n1(t),n2(t))>0 for t0 a.s.

    Proof. Using Itô's formula, we obtain from system (2.5) that

    {dlnx1(t)=[a1b1x1(t)+c1m2(t)(α211+α212)/2]dt+α11dB1(t)+α12dB2(t),dlnx2(t)=[a2b2x2(t)+c2m1(t)(α221+α222)/2]dt+α21dB1(t)+α22dB2(t). (3.3)

    Define a C2-function U(X(t)) by

    U(X(t))=2i=1(xi1lnxi+mi1lnmi+ni1lnni). (3.4)

    Applying Itô's formula to Eq (3.4) leads to

    dU(X(t))=LU(X(t))+2i=1(α1ix1(t)dBi(t)α1idBi(t)+α2ix2(t)dBi(t)α2idBi(t)),

    where

    LU(X(t))=b1x21b2x22+c1m2x1+c2m1x2+a1x1+a2x2+b1x1+b2x2+σ1x11+x1LU(X(t))=+σ2x21+x2+(α211+α212)/2+(α221+α222)/2σ11n1x11+x1σ21n2x21+x2LU(X(t))=+2σ1+2σ2a1a2c1m2c2m1σ1m1σ2m2σ1n1m1σ2n2m2LU(X(t))K+3σ1+3σ2+(α211+α212)/2+(α221+α222)/2,

    and

    K=b1x21b2x22+c1m2x1+c2m1x2+a1x1+a2x2+b1x1+b2x2.

    It follows from Lemma 3.1 that m11 and m21, and then K is bounded when x1,x2(0,+). As a consequence, LU(X(t)) is bounded. The rest proof is similar to that of Theorem 2.1 in [46], and hence we omit it.

    Assign ξ1=0.5(α211+α212), ξ2=0.5(α221+α222). The following Theorems 3.1-3.4 focus on the survival results of both species.

    Theorem 3.1. Both species are extinct exponentially if a1+c1<ξ1 and a2+c2<ξ2.

    Proof. An integration of Eq (3.3) over [0,t] leads to

    lnxi(t)xi(0)=(aiξi)tbit0xi(s)ds+cit0mj(s)ds+αi1B1(t)+αi2B2(t). (3.5)

    Dividing by t and using Lemma 3.1, one has

    t1lnxi(t)t1lnxi(0)ai+ciξi+t1(αi1B1(t)+αi2B2(t)), i=1,2. (3.6)

    The strong law of local martingales [47] states limt+t1Bi(t)=0, and moreover, we derive from Eq (3.6) that

    lim supt+t1lnxi(t)ai+ciξi, i=1,2.

    Thus, both species are extinct exponentially by the assumptions of Theorem 3.1.

    Theorem 3.2. Assume that a1+c1<ξ1 and a2>ξ2, then species x1 goes to exponential extinction while species x2 is persistent in the mean and limt+x2(t)=(a2ξ2)/b2 a.s.

    Proof. If a1+c1<ξ1, then we obtain from Theorem 3.1 that species x1 will be extinct exponentially and lim supt+t1lnx1(t)<0. Thus, we further derive that

    limt+x1(t)=0  a.s. (3.7)

    An integration of the last four equations of system (2.5) on both sides results in

    mi(t)mi(0)=σi(t0ni(s)dst0mi(s)ds),ni(t)ni(0)=σi(t0xi(s)1+xi(s)dst0ni(s)ds), i=1,2.

    Consequently, we have

    limt+mi(t)mi(0)t=σilimt+(nimi),  limt+ni(t)ni(0)t=σilimt+(xi1+xini),

    furthermore, it follows from Lemma 3.1 that limt+mi(t)/t=0 and limt+ni(t)/t=0. And limt+mi(0)/t=0, limt+ni(0)/t=0. So we have

    limt+mi=limt+ni=limt+xi1+xi, i=1,2. (3.8)

    Next, by Eq (3.7) one gets for arbitrarily small ε>0, there is T>0 such that for tT,

    0<x11+x1<ε/(2c2),

    which together with Eq (3.8) leads to

    0<m1(t)<ε/(2c2). (3.9)

    Let ε<t1lnx2(0)<ε/2 for tT. We obtain from Eqs (3.5) and (3.9) that for tT,

    lnx2(t)(a2ξ2+ε)tb2t0x2(s)ds+α21B1(t)+α22B2(t),lnx2(t)(a2ξ2ε)tb2t0x2(s)ds+α21B1(t)+α22B2(t).

    An application of Lemma 4 in [48] to the above two inequalities gives that

    x2(t)(a2ξ2+ε)/b2, x2(t)(a2ξ2ε)/b2 a.s.

    Thus

    limt+x2(t)=(a2ξ2)/b2

    is acquired by the arbitrariness of ε.

    Theorem 3.3. Suppose that a1>ξ1 and a2+c2<ξ2, then species x2 goes to exponent extinction while species x1 is persistent in the mean and limt+x1(t)=(a1ξ1)/b1 a.s.

    Proof. The proof is similar to that of Theorem 3.2, and hence we omit it.

    Theorem 3.4. Assume that a1>ξ1 and a2>ξ2, then both species will be permanent in time average and (a1ξ1)/b1x1x1(a1ξ1+c1)/b1, (a2ξ2)/b2x2x2(a2ξ2+c2)/b2 a.s.

    Proof. Recalling Eq (3.5) and Lemma 3.1, we have

    lnxi(t)lnxi(0)+(aiξi+ci)tbit0xi(s)ds+αi1B1(t)+αi2B2(t),lnxi(t)lnxi(0)+(aiξi)tbit0xi(s)ds+αi1B1(t)+αi2B2(t), i=1,2.

    It follows from Lemma 4 in [48] that

    xi(t)(aiξi+ci)/bi,  xi(t)(aiξi)/bi a.s.

    So the desired conclusion is obtained.

    In this section, to discuss the stationary distribution of system (2.5) we make some preliminaries. Consider the following integral equation

    X(t)=X(t0)+tt0g(s,X(s))ds+kl=1tt0ςl(s,X(s))dBl(s). (4.1)

    Lemma 4.1. [49]. Assume that the coefficients of Eq (4.1) are independent of t and satisfy the following conditions for a constant κ:

    |g(s,x1)g(s,x2)|+kl=1|ςl(s,x1)ςl(s,x2)|κ|x1x2|, |g(s,x)|+kl=1|ςl(s,x)|κ(1+|x|)

    in ORRd+ and there exists a nonnegative C2-function V(x) in Rd+ satisfying LV(x)1 outside some compact set. Then Eq (4.1) exists a solution which has a stationary distribution.

    Remark 4.1. [36]. The condition in Lemma 4.1 may be replaced by the global existence of the solution to Eq (4.1) according to Remark 5 in Xu et al. [50].

    We first give Lemma 4.2 which is important for the subsequent discussions.

    Lemma 4.2. Assume that X(t) is a solution to system (2.5) with initial value X(0)>0. Then there is a positive constant Qq such that for q>0,

    E[xqi]Qq, E[mqi]Qq, E[nqi]Qq, i=1,2.

    Proof. Let

    V(X(t))=2i=1(1qxqi+bi2σimq+1i+bi2σinq+1i). (4.2)

    Applying Itô's formula to Eq (4.2), one can derive that

    dV(X(t))=LV(X(t))dt+2i=1(αi1dB1(t)+αi2dB2(t))xqi,

    in which

    LV(X(t))=(a1b1x1+c1m2)xq1+(a2b2x2+c2m1)xq2+2i=112(q1)(α2i1+α2i2)xqiLV(X(t))=+2i=1[bi2(q+1)(nimqimq+1i)+bi2(q+1)(xi1+xinqinq+1i)]. (4.3)

    Obviously, we get, by Young's inequality, that

    bi2(q+1)(nimqimq+1i)bi2(q+1)[1q+1nq+1i1q+1mq+1i]=bi2(nq+1imq+1i),bi2(q+1)(xi1+xinqinq+1i)bi2(q+1)[1q+1(xi1+xi)q+11q+1niq+1]bi2(xq+1iniq+1).

    It follows from Lemma 3.1 that m11 and m21. By Eq (4.3) we have

    LV(X(t))2i=1{bi2xq+1i+[ai+ci+12(q1)(α2i1+α2i2)]xqibi2mq+1i}.

    For a constant η>0, we have

    L(eηtV(X(t)))=ηeηtV(X(t))+eηtLV(X(t))Leηt2i=1{bi2xq+1i+[ai+ci+12(q1)(α2i1+α2i2)+ηq]xqi+(biη2σibi2)mq+1i+biη2σinq+1i}.

    Choosing the above constant η small enough such that biη/(2σi)bi/2<0, and noting that biη/(2σi)nq+1ibiη/(2σi) (see Lemma 3.1, ni1), we further obtain

    L(eηtV(X(t)))G1eηt, (4.4)

    where

    G1=maxx1,x2(0,+)2i=1{bi2xq+1i+[ai+ci+12(q1)(α2i1+α2i2)+ηq]xqi+biη2σi}.

    Integrating Eq (4.4) from 0 to t and then taking the expectation, one has

    E[V(X(t))]eηtV(X(0))+G1/η,  t0,

    which together with the continuity of V(X(t)) and the boundedness of eηtV(X(0)) and G1/η, implies that there exists a constant G2>0 such that for all t0

    E[V(X(t))]G2.

    We further obtain from Eq (4.2) that E[xqi/q]E[V(X(t))]G2, and hence

    E[xqi]qG2, i=1,2.

    Also, it follows from Eq (4.2) that E[mq+1i]2σiG2/bi. And by the Young's inequality, there exist A1i>0 such that

    E[mqi]A1iE[mq+1i]qq+1A1i(2σiG2/bi)qq+1, i=1,2.

    Similarly, we can prove there exist A2i such that

    E[nqi]A2i(2σiG2/bi)qq+1, i=1,2.

    Let

    Qq=max{qG2,A1i(2σiG2/bi)qq+1,A2i(2σiG2/bi)qq+1, i=1,2},

    then for q>0,

    E[xqi]Qq,  E[mqi]Qq,  E[nqi]Qq. (4.5)

    The proof is complete.

    Lemma 4.3. Suppose that X(t) is a solution to system (2.5) with X(0)>0, then almost every path of X(t) to system (2.5) will be uniformly continuous.

    Proof. First let us consider x1(t). For any 0t1t2, an integration of the first equation of system (2.5) yields

    x1(t2)x1(t1)=t2t1x1(s)(a1b1x1(s)+c1m2(s))ds+2i=1α1it2t1x1(s)dBi(s). (4.6)

    Let p>2, by the elementary inequality |a+b+c|p3p1(|ap+bp+cp|), one has

    E[|x1(t2)x1(t1)|p]=E[|t2t1x1(s)(a1b1x1(s)+c1m2(s))ds+2i=1α1it2t1x1(s)dBi(s)|p]3p1{E[|t2t1x1(s)(a1b1x1(s)+c1m2(s))ds|p]+2i=1E[|t2t1α1ix1(s)dBi(s)|p]}. (4.7)

    Recalling Lemma 4.2 (see Eq (4.5)) and using the Hölder inequality result in

    E[|t2t1x1(s)(a1b1x1(s)+c1m2(s))ds|p]E[|(t2t11pp1ds)p1p(t2t1x1(s)p(a1b1x1(s)+c1m2(s))pds)1p|p](t2t1)p1E[t2t1|x1(s)(a1b1x1(s)+c1m2(s))|pds](t2t1)p1t2t112(E[|x1(s)|2p]+E[|a1b1x1(s)+c1m2(s)|2p])ds(t2t1)p1t2t112(E[|x1(s)|2p]+32p1(a2p1+b2p1E[|x1(s)|2p]+c2p1E[|m2(s)|2p]))ds(t2t1)p1t2t112[Q2p+32p1(a2p1+b2p1Q2p+c2p1Q2p)]ds=12(t2t1)p[Q2p+32p1(a2p1+b2p1Q2p+c2p1Q2p)]. (4.8)

    In addition, using the Moment inequality and Lemma 4.2 leads to

    E[|t2t1α11x1(s)dB1(s)|p]+E[|t2t1α12x1(s)dB2(s)|p](αp11+αp12)(p(p1)2)p2(t2t1)p22t2t1E[|x1(s)|p]ds=(αp11+αp12)(p(p1)2(t2t1))p2Qp. (4.9)

    Substituting Eqs (4.8) and (4.9) into Eq (4.7), we have

    E[|x1(t2)x1(t1)|p]F1(t2t1)p2, (4.10)

    where

    F1=3p1[12(t2t1)p2(Q2p+32p1(a2p1+b2p1Q2p+c2p1Q2p))+(αp11+αp12)(p(p1)2)p2Qp].

    Next, we continue to consider m1(t). For any 0t1t2, integrating the third equation of system (2.5) from t1 to t2 yields that

    m1(t2)m1(t1)=t2t1σ1(n1(s)m1(s))ds.

    Similar to Eq (4.7), we have from the Hölder inequality and Lemma 4.2 that

    E[|m1(t2)m1(t1)|p]=E[|t2t1σ1(n1(s)m1(s))ds|p]E[|(t2t11pp1ds)p1p(t2t1σp1(n1(s)m1(s))pds)1p|p](t2t1)p1t2t1E[|σ1(n1(s)m1(s))|p]ds(t2t1)p1t2t12p1(σp1E[|n1(s)|p]+σp1E[|m1(s)|p])dsF2(t2t1)p2, (4.11)

    where F2=2p(t2t1)p2σp1Qp.

    Finally, we investigate n1(t). For any 0t1t2, by integrating the fifth equation of system (2.5) one has

    n1(t2)n1(t1)=t2t1σ1(x1(s)1+x1(s)n1(s))ds.

    Similar to Eq (4.11), one obtains

    E[|n1(t2)n1(t1)|p]=E[|t2t1σ1(x1(s)1+x1(s)n1(s))ds|p]E[|(t2t11pp1ds)p1p(t2t1σp1(x1(s)1+x1(s)n1(s))pds)1p|p](t2t1)p1t2t1E[|σ1(x1(s)1+x1(s)n1(s))|p]ds(t2t1)p1t2t12p1(σp1E[|x1(s)1+x1(s)|p]+σp1E[|n1(s)|p])ds(t2t1)p1t2t12p1(σp1E[|x1(s)|p]+σp1E[|n1(s)|p])dsF2(t2t1)p2. (4.12)

    Repeating the same analysis method as above, we obtain that x2, m2 and n2 own similar results as those of Eqs (4.10)-(4.12), respectively. Thus, it follows from Lemma 3.4 in [50] that almost every sample path of X(t) is uniformly continuous.

    Lemma 4.4. [51]. Let h(t) be a nonnegative function defined on [0,+) such that h(t) is integrable on [0,+) and is uniformly continuous on [0,+). Then limt+h(t)=0.

    Lemma 4.5. If b1b2c1c2>0, then the solution X(t)=(x1(t),x2(t),m1(t),m2(t),n1(t), n2(t))>0 to system (2.5) is globally attractive, that is, for any solution ˉX(t)=(ˉx1(t),ˉx2(t), ˉm1(t),ˉm2(t),ˉn1(t),ˉn2(t)) to system (2.5) with ˉX(0)>0, there exist limt+|xi(t)ˉxi(t)|=0, limt+|mi(t)ˉmi(t)|=0, limt+|ni(t)ˉni(t)|=0 a.s., i=1,2.

    Proof. It follows from the last two equations of system (2.5) that

    d(ni(t)ˉni(t))={σi(xi(t)1+xi(t)ˉxi(t)1+ˉxi(t))σi(ni(t)ˉni(t))}dt, i=1,2. (4.13)

    Integrating both sides of Eq (4.13) over the interval [0,t] yields that

    ni(t)ˉni(t)=(ni(0)ˉni(0))eσit+σieσitt0eσis(xi(s)1+xi(s)ˉxi(s)1+ˉxi(s))ds.

    As a consequence, one has

    |ni(t)ˉni(t)||ni(0)ˉni(0)|eσit+σieσitt0eσis|xi(s)1+xi(s)ˉxi(s)1+ˉxi(s)|ds.

    Note that

    |xi(t)1+xi(t)ˉxi(t)1+ˉxi(t)|=|xi(t)ˉxi(t)(1+xi(t))(1+ˉxi(t))||xi(t)ˉxi(t)|,

    we have

    |ni(t)ˉni(t)||ni(0)ˉni(0)|eσit+σieσitt0eσis|xi(s)ˉxi(s)|ds, (4.14)

    from which we conclude that

    t0|ni(s)ˉni(s)|ds1σi(eσit1)|ni(0)ˉni(0)|+σit0dνν0eσi(sν)|xi(s)ˉxi(s)|dst0|ni(s)ˉni(s)|ds=1σi(1eσit)|ni(0)ˉni(0)|+σit0eσis|xi(s)ˉxi(s)|dstseσiνdνt0|ni(s)ˉni(s)|ds=1σi(1eσit)|ni(0)ˉni(0)|+t0|xi(s)ˉxi(s)|(1eσi(st))dst0|ni(s)ˉni(s)|ds1σi|ni(0)ˉni(0)|+t0|xi(s)ˉxi(s)|ds, i=1,2. (4.15)

    Similarly, one has

    t0|mi(s)ˉmi(s)|ds1σi|mi(0)ˉmi(0)|+t0|ni(s)ˉni(s)|ds, i=1,2. (4.16)

    Assign

    μ=b1b2c1c2,  M(t)=b2+c2μ|lnx1(t)lnˉx1(t)|+b1+c1μ|lnx2(t)lnˉx2(t)|. (4.17)

    A direct calculation of the right differential D+M(t) of M(t) leads to

    D+M(t)=b2+c2μsgn{x1(t)ˉx1(t)}d(lnx1(t)lnˉx1(t))+b1+c1μsgn{x2(t)ˉx2(t)}d(lnx2(t)lnˉx2(t))b2+c2μ(c1|m2(t)ˉm2(t)|b1|x1(t)ˉx1(t)|)dt+b1+c1μ(c2|m1(t)ˉm1(t)|b2|x2(t)ˉx2(t)|)dt,

    from which and Eqs (4.15) and (4.16) one can obtain

    M(t)M(0)Mb2+c2μ[c1σ2|m2(0)ˉm2(0)|+c1t0|n2(s)ˉn2(s)|dsb1t0|x1(s)ˉx1(s)|ds]M(t)+b1+c1μ[c2σ1|m1(0)ˉm1(0)|+c2t0|n1(s)ˉn1(s)|dsb2t0|x2(s)ˉx2(s)|ds]Mc1(b2+c2)σ2μ|m2(0)ˉm2(0)|+c1(b2+c2)μ[1σ2|n2(0)ˉn2(0)|+t0|x2(s)ˉx2(s)|ds]M(t)+c2(b1+c1)σ1μ|m1(0)ˉm1(0)|+c2(b1+c1)μ[1σ1|n1(0)ˉn1(0)|+t0|x1(s)ˉx1(s)|ds]M(t)b1(b2+c2)μt0|x1(s)ˉx1(s)|dsb2(b1+c1)μt0|x2(s)ˉx2(s)|dsM=c1(b2+c2)σ2μ|m2(0)ˉm2(0)|+c1(b2+c2)σ2μ|n2(0)ˉn2(0)|t0|x1(s)ˉx1(s)|dsM(t)+c2(b1+c1)σ1μ|m1(0)ˉm1(0)|+c2(b1+c1)σ1μ|n1(0)ˉn1(0)|t0|x2(s)ˉx2(s)|ds.

    Rearranging the above inequality leads to

    M(t)+2i=1t0|xi(s)ˉxi(s)|dsM(0)+c1(b2+c2)σ2μ(|m2(0)ˉm2(0)|+|n2(0)ˉn2(0)|)M(t)+2i=1t0|xi(s)ˉxi(s)|ds+c2(b1+c1)σ1μ(|m1(0)ˉm1(0)|+|n1(0)ˉn1(0)|)<+,

    from which one gets |xi(t)ˉxi(t)|L1[0,+). Similarly, it follows from Eqs (4.15) and (4.16) that |mi(t)ˉmi(t)|,|ni(t)ˉni(t)|L1[0,+). Thus, we obtain from Lemmas 4.3 and 4.4 that

    limt+|xi(t)ˉxi(t)|=limt+|mi(t)ˉmi(t)|=limt+|ni(t)ˉni(t)|=0, i=1,2,

    which confirms Lemma 4.5.

    Theorem 4.1. If a1ξ1c1>0, a2ξ2c2>0 and b1b2c1c2>0, then system (2.5) admits a unique stationary distribution.

    Proof. To finish this proof, we will consider the following two steps.

    Step 1: We first prove the existence of stationary Markov process.

    It follows from Lemma 4.1 and Remark 4.1 that we only need to find a nonnegative C2-function W(X(x1,x2,m1,m2,n1,n2)) and a closed set UR6+ such that LW(X)1 on XR6+U. Let q>1 and

    W(X)=δ1(lnx1+c1σ2n2)+δ2(lnx2+c2σ1n1)W(X(t))=+2i=1{1qxqi+12σin2i1σilnni+14σim2i12σilnmi}, (4.18)

    where δi=2λimax{2,Hi},λi=aiξici,i=1,2, and the constants Hi>0 will be given later. An application of Itô's formula and Lemma 3.1 gives

    LW(X)δ1λ1b1xq+11+[a1+12(q1)(α211+α212)+c1]xq1+b1δ1x11n1x11+x1LW(X)=δ2λ2b2xq+12+[a2+12(q1)(α221+α222)+c2]xq2+b2δ2x21n2x21+x2LW(X)=14m2114m2234n2134n2212m1n112m2n2+5. (4.19)

    Choose ϵ>0 sufficiently small such that

    0<ϵ<min{λi4bi,[bi2(H3+6)]1q+1,[14(H3+6)]14,[34(H3+6)]14,12(H3+6),1+4/(H3+6)12},

    i=1,2, where the constant H3>0 is supplied later. A bounded closed set is defined by

    Uϵ={XR6+|ϵxi1ϵ, ϵ3mi1ϵ2, ϵ2ni1ϵ2}, i=1,2.

    Assign

    Uϵ1={XR6+|0<x1<ϵ}, Uϵ2={XR6+|0<x2<ϵ},Uϵ3={XR6+|x1>1ϵ}, Uϵ4={XR6+|x2>1ϵ},Uϵ5={XR6+|m1>1ϵ2}, Uϵ6={XR6+|m2>1ϵ2},Uϵ7={XR6+|n1>1ϵ2}, Uϵ8={XR6+|n2>1ϵ2},Uϵ9={XR6+|0<m1<ϵ3,n1>ϵ2,n2>ϵ2}, Uϵ10={XR6+|0<m2<ϵ3,n1>ϵ2,n2>ϵ2},Uϵ11={XR6+|0<n1<ϵ2,x1>ϵ,x2>ϵ}, Uϵ12={XR6+|0<n2<ϵ2,x1>ϵ,x2>ϵ}.

    To prove that LW(X)1 for XR6+Uϵ, we will consider the following six cases.

    Case 1. When XUϵ1, one has from Eq (4.19) that

    LW(X)12b1xq+11δ1λ14δ1λ14+b1δ1ϵδ1λ12+H1,

    where

    H1=sup(x1,x2)R2+{12b1xq+11+[a1+12(q1)(α211+α212)+c1]xq1H1=sup(x1,x2)R2+b2xq+12+[a2+12(q1)(α221+α222)+c2]xq2+b2δ2x2+5}.

    We have from δ1=2λ1max{2,H1} that δ1λ1/41. Then

    LW(X)12b1xq+11δ1λ14δ1λ141.

    Similarly, for XUϵ2 and δ2=2λ2max{2,H2}, one has

    LW(X)12b2xq+12δ2λ24δ2λ24+δ2b2ϵδ2λ22+H2δ2λ241,

    where

    H2=sup(x1,x2)R2+{12b2xq+12+[a2+12(q1)(α221+α222)+c2]xq2H2=sup(x1,x2)R2+b1xq+11+[a1+12(q1)(α211+α212)+c1]xq1+b1δ1x1+5}.

    To discuss the following Cases 2-6, we reconsider Eq (4.19) and obtain

    LW(X)b12xq+111n1x11+x114m2134n21n12m1LW(X)=b22xq+121n2x21+x214m2234n22n22m2+H3+5, (4.20)

    where

    H3=sup(x1,x2)R2+{12b1xq+11+[a1+12(q1)(α211+α212)+c1]xq1+b1δ1x1H3=sup(x1,x2)R2+12b2xq+12+[a2+12(q1)(α221+α222)+c2]xq2+b2δ2x2}.

    Case 2. When XUϵ3, it follows from Eq (4.20) that LW(X)H3+512b1ϵ(q+1)1. Similarly, if XUϵ4, then LW(X)H3+512b2ϵ(q+1)1.

    Case 3. When XUϵ5 and XUϵ6, one has LW(X)H3+5m2i4<H3+514ϵ41.

    Case 4. When XUϵ7 and XUϵ8, then LW(X)H3+53n2i4<H3+534ϵ41.

    Case 5. When XUϵ9 and XUϵ10, we get LW(X)H3+512mini<H3+512ϵ3ϵ21.

    Case 6. When XUϵ11 and XUϵ12, then LW(X)H3+51nixi1+xi<H3+51ϵ2ϵ1+ϵ1.

    From the above discussions we know the closed set Uϵ satisfying supXR6+UϵLW(X)1.

    Step 2: When b1b2c1c2>0, we know from Lemma 4.5 that the solution X(t) is globally attractive.

    Combining Step 1 and Step 2, we complete the proof of Theorem 4.1.

    In this section, we will employ several specific examples to simulate the solutions to system (2.5), and verify the analytical results of the previous section.

    For system (2.5), we first fix the parameter values as follows: a1=0.295, a2=0.3, b1=0.75, b2=0.65, c1=0.05, c2=0.05, σ1=0.1, σ2=0.2 and initial value x1(0)=0.1 and x2(0)=0.12. We will reveal how two coupling noise sources influence the long-time behaviors by choosing different noise intensities α211, α212, α221 and α222.

    Choose α211=0.652, α212=0.752, α221=0.642, α222=0.742. A calculation gives that a1+c1=0.3<ξ1=0.4925 and a2+c2=0.35<ξ2=0.4786, which surely satisfies Theorem 3.1. Thus, both species will be EE (see Figure 1).

    Figure 1.  Species x1 and x2 are extinct exponentially in system (2.5).

    Choose α211=0.652, α212=0.752, α221=0.032, α222=0.022. By calculating we have a1+c1=0.3<ξ1=0.4925 and a2=0.3>ξ2=0.00065, it then follows from Theorem 3.2 that species x1 is EE while x2 is PM (see Figure 2).

    Figure 2.  Species x1 is extinct exponentially while x2 is persistence in the mean in system (2.5).

    Choose α211=0.032, α212=0.022, α221=0.652, α222=0.752. Since a1=0.295>ξ1=0.00065 and a2+c2=0.35<ξ2=0.4925, Theorem 3.3 indicates that species x1 is PM while x2 is EE (see Figure 3).

    Figure 3.  Species x1 is persistence in the mean while x2 is extinct exponentially in system (2.5).

    Choose α211=0.032, α212=0.022, α221=0.022, α222=0.012. Together with Theorem 3.4, we have from a1=0.295>ξ1=0.00065 and a2=0.3>ξ2=0.00025 that both species are PTA (see Figure 4).

    Figure 4.  Species x1 and x2 are permanent in time average in system (2.5).

    Furthermore, taking the same noise intensities as in Figure 4, a calculation shows that a1ξ1c1=0.24435>0, a2ξ2c2=0.24975>0 and b1b2c1c2=0.485>0. So we know, by Theorem 4.1, that system (2.5) owns a unique stationary distribution (see Figure 5).

    Figure 5.  Blue bar frequency histogram of system (2.5) at time 200; Red line the probability density function (PDF) of its corresponding stationary distribution simulated by 2500 sample trajectories.

    This paper is concerned with a stochastic facultative mutualism model with saturation effect and distributed delays, in which strong kernel functions are incorporated (see model (2.3)). By analyzing a corresponding equivalent system (2.5), a set of easily verifiable sufficient conditions for the survival results and stationary distribution of system (2.5) is established. Note that ξ1=0.5(α211+α212) and ξ2=0.5(α221+α222) and from the above theoretical results, we have the following conclusions:

    ● Theorems 3.1-3.4 imply that large coupling noise intensities are harmful for the survival of both species while suitably small coupling noise intensities are advantage for them (see Figures 1-4).

    ● It follows from Theorems 3.2 and 3.3 that if the intrinsic growth rate of one species is small, the coupling noise intensities are large amplitude and the cooperation from the other species is not enough, then one species will be extinct exponentially (see Figures 2-3). However, if the other species only owns large intrinsic growth rate and relatively small coupling noise intensities, then it will be persistent in the mean (see Figures 2-3).

    ● Compared with the conditions of Theorems 3.1, 3.4 and 4.1, that is, ai+ci<ξi, ξi<ai and ξi<aici (i=1,2), we find that the intrinsic growth rates ai are larger and larger while the coupling noise intensity ξi is smaller and smaller, then both species go from exponent extinction (see Figure 1) to permanence in time average (see Figure 4) to the existence of a unique stationary distribution (see Figure 5). In addition, b1b2c1c2>0 reveals that the effect of interspecific mutualism is less than that of intra-specific competition.

    The authors thank the editor and referees for their careful reading and valuable comments. The work is supported by the College Innovation Team Project of Hubei Provincial Department of Education (No.T201812).

    The authors declare there is no conflict of interest.



    Conflict of interest



    The authors declare no conflict of interest.

    [1] Sharp PA (2009) The centrality of RNA. Cell 136: 577-580.
    [2] Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136: 777-793.
    [3] Fry LE, Patrício MI, Williams J, et al. (2019) Association of messenger RNA level with phenotype in patients with choroideremia: potential implications for gene therapy dose. JAMA Ophthalmol 138: 128-135.
    [4] Li B, Zhang X, Dong Y (2019) Nanoscale platforms for messenger RNA delivery. Wires Nanomed Nanobi 11: e1530.
    [5] Midoux P, Pichon C (2015) Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines 14: 221-234.
    [6] Dannull J, Haley NR, Archer G, et al. (2013) Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123: 3135-3145.
    [7] Van Lint S, Heirman C, Thielemans K, et al. (2013) mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vacc Immunother 9: 265-274.
    [8] Yang J, Arya S, Lung P, et al. (2019) Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant. Nanoscale 11: 21782-21789.
    [9] Le TT, Andreadakis Z, Kumar A, et al. (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19: 305-306.
    [10] Geall AJ, Mandl CW, Ulmer JB (2013) RNA: the new revolution in nucleic acid vaccines. Semin Immunol 25: 152-159.
    [11] Pardi N, Hogan MJ, Porter FW, et al. (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17: 261-279.
    [12] Pascolo S (2015) The messenger's great message for vaccination. Expert Rev Vaccines 14: 153-156.
    [13] Deering RP, Kommareddy S, Ulmer JB, et al. (2014) Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 11: 885-899.
    [14] Liu MA (2010) Immunologic basis of vaccine vectors. Immunity 33: 504-515.
    [15] Jäschke A, Helm M (2003) RNA sex. Chem Biol 10: 1148-1150.
    [16] Pollard C, Rejman J, De Haes W, et al. (2013) Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21: 251-259.
    [17] Vallazza B, Petri S, Poleganov MA, et al. (2015) Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscip Rev RNA 6: 471-499.
    [18] Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, et al. (2020) Nanomedicines to deliver mRNA: State of the art and future perspectives. Nanomaterials 10: 364.
    [19] Versteeg L, Almutairi MM, Hotez PJ, et al. (2019) Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines 7: 122.
    [20] Hekele A, Bertholet S, Archer J, et al. (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2: e52.
    [21] Lindgren G, Ols S, Liang F, et al. (2017) Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol 8: 1539.
    [22] Luo F, Zheng L, Hu Y, et al. (2017) Induction of protective immunity against Toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP). Front Microbiol 8: 605.
    [23] Michel T, Golombek S, Steinle H, et al. (2019) Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA. J Biol Eng 13: 40.
    [24] Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14: 623-628.
    [25] Pardi N, Hogan MJ, Naradikian MS, et al. (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215: 1571-1588.
    [26] Zarghampoor F, Azarpira N, Khatami SR, et al. (2019) Improved translation efficiency of therapeutic mRNA. Gene 707: 231-238.
    [27] Kowalski PS, Rudra A, Miao L, et al. (2019) Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Mol Ther 27: 710-728.
    [28] Reichmuth AM, Oberli MA, Jaklenec A, et al. (2016) mRNA vaccine delivery using lipid nanoparticles. Ther Deliv 7: 319-334.
    [29] Lundstrom K (2009) Alphaviruses in gene therapy. Viruses 1: 13-25.
    [30] Chira S, Jackson CS, Oprea I, et al. (2015) Progresses towards safe and efficient gene therapy vectors. Oncotarget 6: 30675-30703.
    [31] Ku SH, Jo SD, Lee YK, et al. (2016) Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev 104: 16-28.
    [32] Presnyak V, Alhusaini N, Chen YH, et al. (2015) Codon optimality is a major determinant of mRNA stability. Cell 160: 1111-1124.
    [33] Thess A, Grund S, Mui BL, et al. (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23: 1456-1464.
    [34] Wojtczak BA, Sikorski PJ, Fac-Dabrowska K, et al. (2018) 5′-phosphorothiolate dinucleotide cap analogues: Reagents for messenger RNA modification and potent small-molecular inhibitors of decapping enzymes. J Am Chem Soc 140: 5987-5999.
    [35] Li B, Luo X, Dong Y (2016) Effects of chemically modified messenger RNA on protein expression. Bioconjug Chem 27: 849-853.
    [36] Li M, Zhao M, Fu Y, et al. (2016) Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release 228: 9-19.
    [37] Svitkin YV, Cheng YM, Chakraborty T, et al. (2017) N1-methyl-pseudouridine in mRNA enhances translation through eIF2a-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res 45: 6023-6036.
    [38] Oberg AL, Kennedy RB, Li P, et al. (2011) Systems biology approaches to new vaccine development. Curr Opin Immunol 23: 436-443.
    [39] Auffan M, Rose J, Bottero JY, et al. (2009) Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 4: 634-641.
    [40] Treuel L, Jiang X, Nienhaus GU (2013) New views on cellular uptake and trafficking of manufactured nanoparticles. J R Soc Interface 10: 20120939.
    [41] Ulkoski D, Bak A, Wilson JT, et al. (2019) Recent advances in polymeric materials for the delivery of RNA therapeutics. Expert Opin Drug Deliv 16: 1149-1167.
    [42] Pérez-Ortín JE, Alepuz P, Chávez S, et al. (2013) Eukaryotic mRNA decay: Methodologies, pathways, and links to other stages of gene expression. J Mol Biol 425: 3750-3775.
    [43] Pati R, Shevtsov M, Sonawane A (2018) Nanoparticle vaccines against infectious diseases. Front Immunol 9: 2224.
    [44] Means TK, Hayashi F, Smith KD, et al. (2003) The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 170: 5165-5175.
    [45] Boraschi D, Italiani P, Palomba R, et al. (2017) Nanoparticles and innate immunity: new perspectives on host defence. Semin Immunol 34: 33-51.
    [46] Chen YS, Hung YC, Lin WH, et al. (2010) Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21: 195101.
    [47] Wang T, Zou M, Jiang H, et al. (2011) Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci 44: 653-659.
    [48] Xu L, Liu Y, Chen Z, et al. (2012) Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett 12: 2003-2012.
    [49] Tao W, Gill HS (2015) M2e-immobilized gold nanoparticles as influenza A vaccine: role of soluble M2e and longevity of protection. Vaccine 33: 2307-2315.
    [50] Li X, Deng X, Huang Z (2001) In vitro protein release and degradation of poly-d-L-lactide-poly(ethylene glycol) microspheres with entrapped human serum albumin: quantitative evaluation of the factors involved in protein release phases. Pharm Res 18: 117-124.
    [51] Chahal JS, Fang T, Woodham AW, et al. (2017) An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep 7: 252.
    [52] Chahal JS, Khan OF, Cooper CL, et al. (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A 113: E4133-E4142.
    [53] Sharifnia Z, Bandehpour M, Hamishehkar H, et al. (2019) In-vitro transcribed mRNA delivery using PLGA/PEI nanoparticles into human monocyte-derived dendritic cells. Iran J Pharm Res 18: 1659-1675.
    [54] Uchida S, Kinoh H, Ishii T, et al. (2016) Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials 82: 221-228.
    [55] Kaczmarek JC, Patel AK, Kauffman KJ, et al. (2016) Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew Chem Int Ed Engl 55: 13808-13812.
    [56] Patel AK, Kaczmarek JC, Bose S, et al. (2019) Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv Mater 31: e1805116.
    [57] Liu Y, Li Y, Keskin D, et al. (2019) Poly(β-amino esters): Synthesis, formulations, and their biomedical applications. Adv Healthc Mater 8: e1801359.
    [58] Capasso Palmiero U, Kaczmarek JC, Fenton OS, et al. (2018) Poly(β-amino ester)-co-poly(caprolactone) terpolymers as nonviral vectors for mRNA delivery in vitro and in vivo. Adv Healthc Mater 7: e1800249.
    [59] Palamà IE, Cortese B, D'Amone S, et al. (2015) mRNA delivery using non-viral PCL nanoparticles. Biomater Sci 3: 144-151.
    [60] Lacroix C, Humanes A, Coiffier C, et al. (2020) Polylactide-based reactive micelles as a robust platform for mRNA delivery. Pharm Res 37: 30.
    [61] Dong Y, Dorkin JR, Wang W, et al. (2016) Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Lett 16: 842-848.
    [62] Palmerston Mendes L, Pan J, Torchilin VP (2017) Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22: 1401.
    [63] Franiak-Pietryga I, Ziemba B, Messmer B, et al. (2018) Dendrimers as drug nanocarriers: the future of gene therapy and targeted therapies in cancer. Dendrimers: Fundamentals and Applications IntechOpen, 7.
    [64] Islam MA, Xu Y, Tao W, et al. (2018) Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng 2: 850-864.
    [65] Hajam IA, Senevirathne A, Hewawaduge C, et al. (2020) Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens. Vet Res 51: 37.
    [66] McCullough KC, Bassi I, Milona P, et al. (2014) Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo. Mol Ther Nucleic Acids 3: e173.
    [67] Maiyo F, Singh M (2019) Folate-targeted mRNA delivery using chitosan-functionalized selenium nanoparticles: potential in cancer immunotherapy. Pharmaceuticals (Basel) 12: 164.
    [68] Son S, Nam J, Zenkov I, et al. (2020) Sugar-nanocapsules imprinted with microbial molecular patterns for mRNA vaccination. Nano Lett 20: 1499-1509.
    [69] Siewert C, Haas H, Nawroth T, et al. (2019) Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems. Biomaterials 192: 612-620.
    [70] Zeng C, Zhang C, Walker PG, et al. (2020) Formulation and delivery technologies for mRNA vaccines. Current Topics in Microbiology and Immunology Berlin: Springer.
    [71] Scheel B, Teufel R, Probst J, et al. (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35: 1557-1566.
    [72] Schlake T, Thess A, Fotin-Mleczek M, et al. (2012) Developing mRNA-vaccine technologies. RNA Biol 9: 1319-1330.
    [73] Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34: 1-15.
    [74] Schnee M, Vogel AB, Voss D, et al. (2016) An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis 10: e0004746.
    [75] Udhayakumar VK, De Beuckelaer A, McCaffrey J, et al. (2017) Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide. Adv Healthc Mater 6: 1601412.
    [76] Coolen AL, Lacroix C, Mercier-Gouy P, et al. (2019) Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials 195: 23-37.
    [77] Jekhmane S, De Haas R, Paulino da Silva Filho O, et al. (2017) Virus-like particles of mRNA with artificial minimal coat proteins: particle formation, stability, and transfection efficiency. Nucleic Acid Ther 27: 159-167.
    [78] Li J, Sun Y, Jia T, et al. (2014) Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer. Int J Cancer 134: 1683-1694.
    [79] Sun S, Li W, Sun Y, et al. (2011) A new RNA vaccine platform based on MS2 virus-like particles produced in saccharomyces cerevisiaeBiochem Biophys Res Commun 407: 124-128.
    [80] Zhitnyuk Y, Gee P, Lung MSY, et al. (2018) Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem Biophys Res Commun 505: 1097-1102.
    [81] Kauffman KJ, Webber MJ, Anderson DG (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 240: 227-234.
    [82] Kulkarni JA, Cullis PR, Van Der Meel R (2018) Lipid nanoparticles enabling gene therapies: From concepts to clinical utility. Nucleic Acid Ther 28: 146-157.
    [83] Dimitriadis GJ (1978) Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274: 923-924.
    [84] Moon JJ, Suh H, Bershteyn A, et al. (2011) Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 10: 243-251.
    [85] Tyagi RK, Garg NK, Sahu T (2012) Vaccination strategies against malaria: novel carrier(s) more than a tour de force. J Control Release 162: 242-254.
    [86] Adler-Moore J, Munoz M, Kim H, et al. (2011) Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 29: 4460-4468.
    [87] Monslow MA, Elbashir S, Sullivan NL, et al. (2020) Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine 38: 5793-5802.
    [88] Erasmus JH, Archer J, Fuerte-Stone J, et al. (2020) Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection. Mol Ther Methods Clin Dev 18: 402-414.
    [89] Freyn AW, da Silva JR, Rosado VC, et al. (2020) A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther 28: 1569-1584.
    [90] Lo MK, Spengler JR, Welch SR, et al. (2020) Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. J Infect Dis 221: S493-S498.
    [91] Yang T, Li C, Wang X, et al. (2020) Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact Mater 5: 1053-1061.
    [92] Moyo N, Wee EG, Korber B, et al. (2020) Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth. Vaccines (Basel) 8: 360.
    [93] Lou G, Anderluzzi G, Schmidt ST, et al. (2020) Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. J Control Release 325: 370-379.
    [94] Mai Y, Guo J, Zhao Y, et al. (2020) Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol 354: 104143.
    [95] Eygeris Y, Patel S, Jozic A, et al. (2020) Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett 20: 4543-4549.
    [96] Van Hoecke L, Verbeke R, De Vlieger D, et al. (2020) mRNA encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol Ther Nucleic Acids 20: 777-787.
    [97] Zhong Z, Mc Cafferty S, Combes F, et al. (2018) mRNA therapeutics deliver a hopeful message. Nano Today 23: 16-39.
    [98] Bogers WM, Oostermeijer H, Mooij P, et al. (2015) Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211: 947-955.
    [99] Jackson LA, Anderson EJ, Rouphael NG, et al. (2020) An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med . doi: 10.1056/NEJMoa2022483
    [100] Alberer M, Gnad-Vogt U, Hong HS, et al. (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390: 1511-1520.
    [101] Bahl K, Senn JJ, Yuzhakov O, et al. (2017) Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 25: 1316-1327.
    [102] Feldman RA, Fuhr R, Smolenov I, et al. (2019) mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37: 3326-3334.
    [103] Ding Y, Jiang Z, Saha K, et al. (2014) Gold nanoparticles for nucleic acid delivery. Mol Ther 22: 1075-1083.
    [104] Liu J, Miao L, Sui J, et al. (2020) Nanoparticle cancer vaccines: Design considerations and recent advances. Asian J Pharm Sci . doi: 10.1016/j.ajps.2019.10.006
    [105] Yeom JH, Ryou SM, Won M, et al. (2013) Inhibition of xenograft tumor growth by gold nanoparticle-DNA oligonucleotide conjugates-assisted delivery of BAX mRNA. PLoS One 8: e75369.
    [106] Azmi F, Ahmad Fuaad AAH, Skwarczynski M, et al. (2014) Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother 10: 778-796.
    [107] Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: Putting innate immunity to work. Immunity 33: 492-503.
    [108] Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19: 1597-1608.
    [109] Oleszycka E, Lavelle EC (2014) Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 28: 1-5.
    [110] Alving CR (2009) Vaccine adjuvants. Vaccines for Biodefense and Emerging and Neglected Diseases London: Elsevier, 115-129.
    [111] Hussein WM, Liu TY, Skwarczynski M, et al. (2014) Toll-like receptor agonists: a patent review (2011–2013). Expert Opin Ther Pat 24: 453-470.
    [112] Montomoli E, Piccirella S, Khadang B, et al. (2011) Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 10: 1053-1061.
    [113] Mamo T, Poland GA (2012) Nanovaccinology: The next generation of vaccines meets 21st century materials science and engineering. Vaccine 30: 6609-6611.
    [114] Banchereau J, Briere F, Caux C, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
    [115] Oyewumi MO, Kumar A, Cui ZR (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9: 1095-1107.
    [116] Marasini N, Skwarczynski M, Toth I (2014) Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines 13: 1361-1376.
    [117] Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
    [118] Vasilichin VA, Tsymbal SA, Fakhardo AF, et al. (2020) Effects of metal oxide nanoparticles on Toll-like receptor mRNAs in human monocytes. Nanomaterials (Basel) 10: 127.
    [119] Roy R, Kumar D, Sharma A, et al. (2014) ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice. Toxicol Lett 230: 421-433.
    [120] De Temmerman M-L, Rejman J, Demeester J, et al. (2011) Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 16: 569-582.
    [121] Hafner AM, Corthésy B, Merkle HP (2013) Particulate formulations for the delivery of poly(I: C) as vaccine adjuvant. Adv Drug Deliv Rev 65: 1386-1399.
  • This article has been cited by:

    1. Qinglong Wang, Shuqi Zhai, Qi Liu, Zhijun Liu, Stability and optimal harvesting of a predator-prey system combining prey refuge with fuzzy biological parameters, 2021, 18, 1551-0018, 9094, 10.3934/mbe.2021448
    2. Shuqi Zhai, Qinglong Wang, Ting Yu, Fuzzy optimal harvesting of a prey-predator model in the presence of toxicity with prey refuge under imprecise parameters, 2022, 19, 1551-0018, 11983, 10.3934/mbe.2022558
    3. Ke Qi, Zhijun Liu, Lianwen Wang, Qinglong Wang, A nonlinear HCV model in deterministic and randomly fluctuating environments, 2023, 46, 0170-4214, 4644, 10.1002/mma.8792
    4. Xiaojie He, Zhijun Liu, Partial permanence and stationary distribution of a stochastic competitive model with feedback controls and distributed delays, 2022, 1598-5865, 10.1007/s12190-022-01815-x
    5. Xiaojie He, Zhijun Liu, Qinglong Wang, PARTIAL PERMANENCE AND STATIONARY DISTRIBUTION OF A DELAYED STOCHASTIC FACULTATIVE MUTUALISM MODEL WITH FEEDBACK CONTROLS, 2024, 14, 2156-907X, 657, 10.11948/20220405
    6. Yuhong Guo, Zhijun Liu, Xiaojie He, Qinglong Wang, Modeling and dynamic analysis of a stochastic mutualism model with distributed delays, 2023, 173, 09600779, 113725, 10.1016/j.chaos.2023.113725
    7. Narayan Mondal, Subrata Paul, Animesh Mahata, Manajat Ali Biswas, Banamali Roy, Shariful Alam, Study of dynamical behaviors of harvested stage-structured predator–prey fishery model with fear effect on prey under interval uncertainty, 2024, 6, 27731863, 100060, 10.1016/j.fraope.2023.100060
    8. Baoquan Zhou, Hao Wang, Tianxu Wang, Daqing Jiang, Stochastic generalized Kolmogorov systems with small diffusion: I. Explicit approximations for invariant probability density function, 2024, 382, 00220396, 141, 10.1016/j.jde.2023.10.057
  • Reader Comments
  • © 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(13933) PDF downloads(1006) Cited by(19)

Figures and Tables

Figures(3)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog